Centessa Pharmaceuticals PLC
F:260
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Centessa Pharmaceuticals PLC
F:260
|
UK |
|
WuXi Biologics (Cayman) Inc
F:1FW2
|
CN |
|
Duerr AG
F:DUE
|
DE |
|
F
|
Fortec Elektronik AG
DUS:FEV
|
DE |
|
V
|
Vinci SA
XMUN:SQU
|
FR |
|
M
|
Madrigal Pharmaceuticals Inc
F:YDO1
|
US |
|
F
|
Fielmann Group AG
DUS:FIE
|
DE |
|
V
|
Very Good Food Company Inc
DUS:0SI
|
CA |
|
B
|
Basf Se
XMUN:BAS
|
DE |
|
T
|
Teixeira Duarte SA
F:TXC2
|
PT |
|
H
|
High Tide Inc
XMUN:2LYA
|
CA |
|
C
|
China Minsheng Banking Corp Ltd
F:GHFH
|
CN |
|
D
|
Danone SA
SIX:DAN
|
FR |
Shareholder Yield
Current shareholder yield for 
Centessa Pharmaceuticals PLC is
hidden
.
Peers Comparison
Shareholder Yield
Buybacks
Buyback Yield measures how much a company reduces its outstanding shares through repurchases, expressed as a percentage.
This metric directly reflects the company’s efforts to return value to shareholders. By reducing the number of shares, buybacks can increase earnings per share and potentially boost the stock's price.
Peers Comparison
Buybacks
Debt Paydown
Debt Paydown Yield measures the amount of debt a company repays within a specific period, shown as a percentage of its market capitalization.
This metric indicates how the company is using its capital to decrease financial liabilities, which can strengthen its financial health and potentially enhance shareholder value.
Peers Comparison
Debt Paydown
Price Appreciation
Price
Centessa Pharmaceuticals PLC
| Average Annual Return | 38.84% |
| Standard Deviation of Annual Returns | 113.22% |
| Max Drawdown | -86% |
| Market Capitalization | 6.1B EUR |
| Shares Outstanding | 113 044 200 |
| Percentage of Shares Shorted |
N/A
|
